Cancer treatment systems maker BSD Medical (BSDM) said that its MicroThermX Microwave Ablation system has successfully treated 100 patients at hospitals across the U.S. Physicians have used the innovative therapy system to treat patients with liver, kidney and lung cancers.
The Utah-based company also noted that these treatments have delivered revenues from the sale of disposable SynchroWave antennas (used with the MicroThermX system). These high-end antennas, used during ablation treatment, are expected to generate a significant revenue stream moving ahead.
The company also booked revenues from its fee-per-use equipment rental program. BSD Medical’s equipment rental program is aimed at maximizing revenues from MicroThermX products and boost market penetration.
The MicroThermX system reached the U.S. market in December 2010. Subsequently, it was introduced in Europe in January 2011. The MicroThermX system is a transportable, cutting-edge proprietary product, which includes a microwave generator, single-use antennas and a temperature monitoring mechanism. It is capable of generating significant levels of power with one generator. Its usage helps approach larger and more uniform areas of ablation during a procedure.
The MicroThermX system utilizes BSD Medical’s proprietary synchronous phased array technology to deliver precision-guided microwave energy to ablate soft tissues using a single-patient-use disposable antenna.
The minimally-invasive MicroThermX system has been developed to provide treatments as a stand-alone therapy and has applications in open surgical and percutaneous (via needle-puncture of the skin) ablation procedures. The global market for soft tissue ablation has been estimated to exceed $2.3 billion, offering a significant opportunity for BSD Medical.
BSD Medical provides hyperthermia and ablation therapy systems to treat cancer and benign diseases. It competes with established players like Boston Scientific (BSX) and Angiodynamics (ANGO) in the thermal ablation market.
To read this article on Zacks.com click here.
Zacks Investment Research
